1. Basler, C. F., X. Wang, E. Muhlberger, V. Volchkov, J. Paragas, H. D. Klenk, A. Garcia-Sastre, and P. Palese. 2000. The Ebola virus VP35 protein functions as a type IIFN antagonist. Proc. Natl. Acad. Sci. USA97:12289–12294.
2. Bazhutin, N. B., E. F. Belanov, V. A. Spiridonov, A. V. Voitenko, N. A. Krivenchuk, S. A. Krotov, N. I. Omel' chenko, A. I. Tereshchenko, and V. V. Khomichev. 1992. The effect of the methods for producing an experimental Marburg virus infection on the characteristics of the course of the disease in green monkeys. Vopr. Virusol.37:153–156.
3. Biron, C. A., and G. C. Sen. 2001. Interferons and other cytolines, p.321–351. In D. M. Knipe and P. M. Howley (ed.), Fields’ Virology, 4th ed. Lippincott Williams & Wilkins, Philadelphia, Pa.
4. Bulletin of the World Health Organization. 1978. Ebola haemorrhagic fever in Sudan, 1976. Report of a WHO/International Study Team. Bull. W. H. O.56:247–270.
5. Bulletin of the World Health Organization. 1978. Ebola haemorrhagic fever in Zaire, 1976. Bull. W. H. O.56:271–293.